Critical Survey: Annovis Bio (NYSE:ANVS) versus RenovoRx (NASDAQ:RNXT)

Annovis Bio (NYSE:ANVS) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Valuation and Earnings

This table compares Annovis Bio and RenovoRx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$24.59 million	($2.04)	-1.10
RenovoRx	$40,000.00	1,227.78	-$8.81 million	($0.38)	-3.53

RenovoRx has higher revenue and earnings than Annovis Bio. RenovoRx is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Annovis Bio and RenovoRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-206.01%	-158.26%
RenovoRx	N/A	-120.68%	-89.23%

Volatility and Risk

Annovis Bio has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.

Institutional & Insider Ownership

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 9.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Annovis Bio and RenovoRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1	2	3	0	2.33
RenovoRx	1	0	2	0	2.33

Annovis Bio presently has a consensus price target of $17.33, indicating a potential upside of 672.09%. RenovoRx has a consensus price target of $7.50, indicating a potential upside of 459.70%. Given Annovis Bio’s higher probable upside, analysts clearly believe Annovis Bio is more favorable than RenovoRx.

Summary

Annovis Bio beats RenovoRx on 6 of the 11 factors compared between the two stocks.

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.